Trial Summary:

The LIFT study will evaluate the effects of treatment with bovine lactoferrin (bLF) added to breast milk or formula feeds for premature infants weighing less than 1500g at birth. bLF is a potent antimicrobial agent, it stimulates gut maturation, enhances growth of probiotic organisms and has anti-inflammatory and anti-oxidant effects. The aim of this study is to see if adding bLF to feeds increases survival without major morbidity in very low birth weight infants.

Supported By:

NHMRC 

Eligibility:

Babies born weighing less that 1500g and are less than 7 days old.

Registration ID:

ACTRN12611000247976

Participation:

A target of 1500 very low birth weight infants born across Australia and New Zealand.

Australian Lead Group:

NHMRC CTC

Status:

Follow-up

Activation Date:

15/01/2014

Chairs:

Prof William Tarnow-Mordi

Contact:

lift.study@sydney.edu.au